The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and epNET, according to the FDA approval notice. […]
The post FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors first appeared on News Health.
Author : News Health
Publish date : 2025-03-27 06:40:00
Copyright for syndicated content belongs to the linked Source.